on October 14, 2002
Published online before print October 14, 2002, doi: 10.1161/01.CIR.0000036600.39600.66
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 19, 2002
From the Institut für Pharmakologie und Toxikologie (M.B., R.J., K.H., C.A., M.J.L., L.H.), Medizinische Universitätsklinik (F.W.), and Physikalisches Institut (F.W.), Universität Würzburg, Germany, and Department of Cardiovascular Medicine (S.N.), University of Oxford, UK. * To whom correspondence should be addressed. E-mail: hein{at}toxi.uni-wuerzburg.de.
Background—Elevated plasma norepinephrine levels are associated with increased mortality in patients and in animal models with chronic heart failure. To test which Methods and Results—Cardiac pressure overload was induced by transverse aortic constriction. Three months after aortic banding, survival was dramatically reduced in Conclusions—Our results indicate an essential function of
Revised on August 14, 2002
Accepted on August 16, 2002
Feedback Inhibition of Catecholamine Release by Two Different
Marc Brede MD, 
2-Adrenoceptor Subtypes Prevents Progression of Heart Failure
2-adrenoceptor subtypes operate as presynaptic inhibitory receptors to control norepinephrine release in heart failure, we investigated the response of gene-targeted mice lacking 2-adrenoceptor subtypes (2-KO) to chronic left ventricular pressure overload. In addition, we determined the functional consequences of genetic variants of 2-adrenoceptors in human patients with chronic heart failure.2A-KO (52%) and 2C-KO (47%) mice compared with wild-type and 2B-deficient (86%) animals. Excess mortality in 2A- and 2C-KO strains was attributable to heart failure with enhanced left ventricular hypertrophy and fibrosis and elevated circulating catecholamines. The clinical importance of this finding is emphasized by the fact that heart failure patients with a dysfunctional variant of the 2C-adrenoceptor had a worse clinical status and decreased cardiac function as determined by invasive catheterization and by echocardiography.2A- and 2C-adrenoceptors in the prevention of heart failure progression in mice and human patients. Identification of heart failure patients with genetic 2-adrenoceptor variants as well as new 2-receptor subtype-selective drugs may represent novel therapeutic strategies in chronic heart failure and other diseases with enhanced sympathetic activation.
Key words: receptors, adrenergic, alpha • genetics • heart failure • catecholamines
Related Article:
Circulation 2002 106: 2417-2418.
This article has been cited by other articles:
 |
|
 |
|
  N. Beetz, L. Hein, J. Meszaros, R. Gilsbach, F. Barreto, M. Meissner, U. C. Hoppe, A. Schwartz, S. Herzig, and J. Matthes Transgenic simulation of human heart failure-like L-type Ca2+-channels: implications for fibrosis and heart rate in mice Cardiovasc Res, December 1, 2009; 84(3): 396 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Albarran-Juarez, R. Gilsbach, R. P. Piekorz, K. Pexa, N. Beetz, J. Schneider, B. Nurnberg, and L. Hein Modulation of {alpha}2-Adrenoceptor Functions by Heterotrimeric G{alpha}i Protein Isoforms J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 35 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. J. Lott, C. Hogeman, M. Herr, M. Bhagat, A. Kunselman, and L. I. Sinoway Vasoconstrictor responses in the upper and lower limbs to increases in transmural pressure J Appl Physiol, January 1, 2009; 106(1): 302 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Austinat, S. Braeuninger, J. B. Pesquero, M. Brede, M. Bader, G. Stoll, T. Renne, and C. Kleinschnitz Blockade of Bradykinin Receptor B1 but Not Bradykinin Receptor B2 Provides Protection From Cerebral Infarction and Brain Edema * Expanded Materials and Methods Stroke, January 1, 2009; 40(1): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kurnik, M. Muszkat, G. G. Sofowora, E. A. Friedman, W. D. Dupont, M. Scheinin, A. J.J. Wood, and C. M. Stein Ethnic and Genetic Determinants of Cardiovascular Response to the Selective {alpha}2-Adrenoceptor Agonist Dexmedetomidine Hypertension, February 1, 2008; 51(2): 406 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gilsbach, M. Brede, N. Beetz, E. Moura, V. Muthig, C. Gerstner, F. Barreto, S. Neubauer, M. A. Vieira-Coelho, and L. Hein Heterozygous {alpha}2C-adrenoceptor-deficient mice develop heart failure after transverse aortic constriction Cardiovasc Res, September 1, 2007; 75(4): 728 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Knaus, X. Zong, N. Beetz, R. Jahns, M. J. Lohse, M. Biel, and L. Hein Direct Inhibition of Cardiac Hyperpolarization-Activated Cyclic Nucleotide-Gated Pacemaker Channels by Clonidine Circulation, February 20, 2007; 115(7): 872 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dunnick, P. Blackshear, G. Kissling, M. Cunningham, J. Parker, and A. Nyska Critical Pathways in Heart Function: Bis(2-chloroethoxy)methane-Induced Heart Gene Transcript Change in F344 Rats Toxicol Pathol, June 1, 2006; 34(4): 348 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Li, R. M. Canham, W. Vongpatanasin, D. Leonard, R. J. Auchus, and R. G. Victor Do Allelic Variants in {alpha}2A and {alpha}2C Adrenergic Receptors Predispose to Hypertension in Blacks? Hypertension, June 1, 2006; 47(6): 1140 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Metra, C. Zani, L. Covolo, S. Nodari, N. Pezzali, U. Gelatti, F. Donato, G. Nardi, and L. D. Cas Role of {beta}1- and {alpha}2c-adrenergic receptor polymorphisms and their combination in heart failure: A case-control study Eur J Heart Fail, March 1, 2006; 8(2): 131 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Regitz-Zagrosek, B. Hocher, M. Bettmann, M. Brede, K. Hadamek, C. Gerstner, H. B. Lehmkuhl, R. Hetzer, and L. Hein {alpha}2C-Adrenoceptor polymorphism is associated with improved event-free survival in patients with dilated cardiomyopathy Eur. Heart J., February 2, 2006; 27(4): 454 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Munch, K. Rosport, A. Bultmann, C. Baumgartner, Z. Li, L. Laacke, and M. Ungerer Cardiac Overexpression of the Norepinephrine Transporter Uptake-1 Results in Marked Improvement of Heart Failure Circ. Res., October 28, 2005; 97(9): 928 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Shafaroudi, M. McBride, C. Deighan, A. Wokoma, J. Macmillan, C. J. Daly, and J. C. McGrath Two "Knockout" Mouse Models Demonstrate That Aortic Vasodilatation Is Mediated via {alpha}2A-Adrenoceptors Located on the Endothelium J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 804 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. I. Sinoway and J. Li A perspective on the muscle reflex: implications for congestive heart failure J Appl Physiol, July 1, 2005; 99(1): 5 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kaye and M. Esler Sympathetic neuronal regulation of the heart in aging and heart failure Cardiovasc Res, May 1, 2005; 66(2): 256 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Kaye, B. Smirk, S. Finch, C. Williams, and M. D. Esler Interaction between cardiac sympathetic drive and heart rate in heart failure: Modulation by adrenergic receptor genotype J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2008 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Small, J. Mialet-Perez, C. A. Seman, C. T. Theiss, K. M. Brown, and S. B. Liggett Polymorphisms of cardiac presynaptic {alpha}2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects PNAS, August 31, 2004; 101(35): 13020 - 13025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Barki-Harrington, C. Perrino, and H. A Rockman Network integration of the adrenergic system in cardiac hypertrophy Cardiovasc Res, August 15, 2004; 63(3): 391 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Kirstein and P. A. Insel Autonomic Nervous System Pharmacogenomics: A Progress Report Pharmacol. Rev., March 1, 2004; 56(1): 31 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Lohse, S. Engelhardt, and T. Eschenhagen What Is the Role of {beta}-Adrenergic Signaling in Heart Failure? Circ. Res., November 14, 2003; 93(10): 896 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Y. Oudit, M. A. Crackower, U. Eriksson, R. Sarao, I. Kozieradzki, T. Sasaki, J. Irie-Sasaki, D. Gidrewicz, V. O. Rybin, T. Wada, et al. Phosphoinositide 3-Kinase {gamma}-Deficient Mice Are Protected From Isoproterenol-Induced Heart Failure Circulation, October 28, 2003; 108(17): 2147 - 2152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liao, S. Takashima, Y. Asano, M. Asakura, A. Ogai, Y. Shintani, T. Minamino, H. Asanuma, S. Sanada, J. Kim, et al. Activation of Adenosine A1 Receptor Attenuates Cardiac Hypertrophy and Prevents Heart Failure in Murine Left Ventricular Pressure-Overload Model Circ. Res., October 17, 2003; 93(8): 759 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-s. Liang Sympatholysis and cardiac sympathetic nerve function in the treatment of congestive heart failure J. Am. Coll. Cardiol., August 6, 2003; 42(3): 549 - 551. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brede, G. Nagy, M. Philipp, J. B. Sorensen, M. J. Lohse, and L. Hein Differential Control of Adrenal and Sympathetic Catecholamine Release by {alpha}2-Adrenoceptor Subtypes Mol. Endocrinol., August 1, 2003; 17(8): 1640 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Cohn Sympathetic Nervous System in Heart Failure Circulation, November 5, 2002; 106(19): 2417 - 2418. [Full Text] [PDF]
|
|